DNA topoisomerase targeting drugs: Mechanisms of action and perspectives

Anti-Cancer Drugs

Volumn 8, Issue 9, 1997, Pages 811-822

  Malonne, Hugues ^a   Atassi, Ghanem ^a,b  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

DNA; Mechanism of action; Topoisomerase

Indexed keywords

ACLARUBICIN; AMONAFIDE; AMSACRINE; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DACTINOMYCIN; DAUNORUBICIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ELLIPTICINE; ELLIPTICINE DERIVATIVE; ELLIPTINIUM ACETATE; ETOPOSIDE; FOSTRIECIN; GENISTEIN; IDARUBICIN; INTOPLICINE; MENADIONE; MENOGARIL; MERBARONE; MITOXANTRONE; OLIVACINE; QUERCETIN; RUFOCROMOMYCIN; TOPOTECAN; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER; DNA BINDING; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG RESISTANCE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; HUMANS;

EID: 0030663042     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199710000-00001     Document Type: Review

References (110)

1. Wang JC. Interaction between DNA and an Escherichia coli protein omega. J Mol Biol 1971; 55: 523-33.
2. Champoux JJ, Dulbecco R. An activity from mammalian cells that untwists superhelical DNA - a possible swivel for DNA replication (polyoma-ethidium bromide-mouse-embryo cells-dye binding assay). Proc Natl Acad Sci USA 1972; 69: 143-6.
3. Gellert M, Mizuuchi K, O'Dea MH, Nash HA. DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci USA 1976; 73: 3872-6.
4. Liu LF, Liu CC, Alberts BM. T4 DNA topoisomerase: a new ATP-dependent enzyme essential for initiation of T4 bacteriophage DNA replication. Nature 1979; 281: 456-61.
5. Gellert M. DNA topoisomerases. Annu Rev Biochem 1981; 50: 879-910.
6. Miller KG, Liu LF, Englund PT. A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J Biol Chem 1981; 256: 9334-9.
7. Halligan BD, Edwards KA, Liu LF. Purification and characterization of a type II DNA topoisomerase from bovine calf thymus. J Biol Chem 1985; 260: 2475-82.
8. Corbett AH, Zechiedrich EL, Osheroff N. A role for the passage helix in the DNA cleavage reaction of eukaryotic topoisomerase II. A two-site model for enzyme-mediated DNA cleavage. J Biol Chem 1992; 267: 683-6.
9. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994; 34: 191-218.
10. Wang JC. DNA topoisomerases. Annu Rev Biochem 1985; 54: 665-97.
11. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989; 58: 351-75.
12. Hsiang YH, Jiang JB, Liu LF. Topoisomerase H-mediated DNA cleavage by amonafide and its structural analogs. Mol Pharmacol 1989; 36: 371-6.
13. Markovits J, Linassier C, Fosse P, et al. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 1989; 49: 5111-7.
14. Yamashita Y, Kawada S, Nakano H. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem Pharmacol 1990; 39: 737-44.
15. Yamashita Y, Kawada S, Fujii N, Nakano H. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry 1991; 30: 5838-45.
16. Kawada S, Yamashita Y, Fujii N, Nakano H. Induction of a heat-stable topoisomerase II-DNA cleavable complex by nonintercalative terpenoides, terpentecin and clerocidin. Cancer Res 1991; 51: 2922-5.
17. Drake FH, Hofmann GA, Mong SM, et al. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 1989; 49: 2578-83.
18. Boritzki TJ, Wolfard TS, Besserer JA, Jackson RC, Fry DW. Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol 1988; 37: 4063-8.
19. Tanabe K, Ikegami Y, Ishida R, Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 1991; 51: 4903-8.
20. Leteurtre F, Madalengoitia J, Orr A, el at. Rational design and molecular effects of a new topoisomerase II inhibitor, azatoxin. Cancer Res 1992; 52: 4478-83.
21. Gewirtz DA. Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors? Biochem Pharmacol 1991; 42: 2253-8.
22. De Isabella P, Capranico G, Palumbo M, Sissi C, Krapcho AP, Zunino F. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects. Mol Pharmacol 1993; 43: 715-21.
23. Onishi Y, Azuma Y, Kizaki H. Bis(2,6-dioxopiperaxine) derivatives, topoisomerase II inhibitors which do not form a DNA cleavable complex, induce thymocyte apoptosis. Biochem Mol Biol Int 1994; 32: 115-22.
24. Capranico G, Butelli E, Zunino F. Change of the sequence specificity of daunorubicin-stimulated topoisomerase II DNA cleavage by epimerization of the amino group of the sugar moiety. Cancer Res 1995; 55: 312-7.
25. Hwang JL, Shyy SH, Chen AY, Juan CC, Whang-Peng J. Studies of topoisomerase-specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide. Cancer Res 1989; 49: 958-62.
26. Hsiang YH, Wu HY, Liu LF. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 1988; 48: 3230-5.
27. Atassi G, Dumont P, Pepin O, Gras O, Gros P. SR95325B, a new ellipticine derivative highly active against established marine solid tumors. Proc Am Ass Cancer Res 1989; 30: abstr 2458.
28. Atassi G, Pepin O, Dumont P, Gros P. SR95325A (BD84): a new antitumor agent. Invest New Drugs 1989; 7: 457.
29. Pierson V, Pierre A, de Cointet P, Nguyen CH, Bisagni E, Gros P. Interrelationship between affinity for DNA, cytotoxicity and induction of DNA-breaks in cultured L1210 cells for two series of tricyclic intercalators. Simplified analogues of ellipticine derivatives. Biochem Pharmacol 1989; 38: 1395-406.
30. LoRusso PM, Demchick LL, Mondenis JM, et al. Preclinical antitumor activity of SR26050. Proc Am Ass Cancer Res 1992; 33: abstr 318.
31. Nguyen GH, Bisagni E, Lavelle F, Bissery MC, Huel C. Synthesis and antitumor properties of new 4-methyl-substituted pyrido[4,3-b]indoles (gamma-carbolines). Anticancer Drug Des 1992; 7: 219-33.
32. Boogaard AT, Pandit UK, Koomen GJ. Ring D modification of ellipticine. Part I. New ellipticine derivatives from 1-cyano-6-methylellipticine. Tetrahedron 1994; 52: 2551-60.
33. Anderson WK, Gopalsamy A, Reddy PS. Design, synthesis, and study of 9-substituted ellipticine and 2-methylellipticinium analogues as potential CNS-selective antitumor agents. J Med Chem 1994; 37: 1955-63.
34. Capranico G, Zunino F, Kohn KW, Pommier Y. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry 1990; 29: 562-9.
35. Pommier Y, Capranico G, Orr A, Kohn KW. Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucleic Acids Res 1991; 19: 5973-80.
36. Jaxel C, Capranico G, Kerrigan D, Kohn KW, Pommier Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 1991; 266: 20418-23.
37. Schneider E, Darkin SJ, Lawson PA, Ching LM, Ralph RK, Baguley BC. Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II. Eur J Cancer Clin Oncol 1988; 24: 1783-90.
38. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-8.
39. Judson IR. Anthrapyrazoles: true successors to the anthracyclines? Anti-Cancer Drugs 1991; 2: 223-31.
40. Fosse P, Rene B, Charra M, Paoletti C, Saucier JM. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationship. Mol Pharmacol 1992; 42: 590-5.
41. Riou JF, Fosse P, Bissery MC, et al. RP60475 and derivatives, a new class of antitumor agents inhibiting both topoisomerases I and II activity. Proc Am Ass Cancer Res 1992; 33: abstr 437.
42. Le Mee S, Markovitz J, Pierre A, et al. In vitro studies of S16020-2, a new antitumor activity of pyridocarbazole derivative. Proc 5th Conf on DNA Topoisomerases Therapy, New York, 1994.
43. Luo Y, Ren YF, Chou TC, et al. A structure-activity relationship study of batracylin analogues. Pharmac Res 1993; 10: 918-23.
44. Andersson BS, Beran M, Bakic M, Silberman LE, Newman RA, Zwelling LA. In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafldimide: NSC, 308847) in human leukemia. Cancer Res 1987; 47: 1040-4.
45. Larsen AK, Grondard L, Couprie J, et al. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmacol 1993; 46: 1403-12.
46. Oka H, Yoshinari T, Murai T, et al. A new topoisomerase-II inhibitor, BE-10988, produced by a streptomycete. I. Taxonomy, fermentation, isolation and characterization. J Antibiot (Tokyo) 1991; 44: 486-91.
47. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259: 13560-6.
48. Robinson MJ, Martin BA, Gootz TD, et al. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J Biol Chem 1991; 266: 14585-92.
49. Sorensen BS, Jensen PS, Andersen AH, et al. Stimulation of topoisomerase II mediated DNA cleavage at specific sequence elements by the 2-nitroimidazole Ro 15-0216. Biochemistry 1990; 29: 9507-15.
50. Riou JF, Helissey P, Grondard L, Giorgi-Renault S. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives. Mol Pharmacol 1991; 40: 699-706.
51. Yamashita Y, Kawada S, Fujii N, Nakano H. Induction of mammalian DNA topoisomerase II dependent DNA cleavage by antitumor antibiotic streptonigrin. Cancer Res 1990; 50: 5841-4.
52. Chen AY, Yu C, Lee WH, Peng LF, Lin LF. Menadione (vitamine K3) induces topoisomerase II-mediated DNA-cleavage. Proc Am Ass Cancer Res 1992; 33: abstr 2588.
53. Jensen PB, Sorensen BS, Demant EJ, et al. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 1990; 50: 3311-6.
54. Foglesong PD, Reckord C, Swink S. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol 1992; 30: 123-5.
55. Funayama Y, Nishio K, Takeda Y, et al. Suramin inhibits the phosphorylation and catalytic activity of DNA topoisomerase II in human lung cancer cells. Anticancer Res 1993; 13: 1981-8.
56. Trask DK, Muller MT. Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D. Proc Natl Acad Sci USA 1988; 85: 1417-21.
57. Poddevin B, Riou JF, Lavelle F, Pommier Y. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol 1993; 44: 767-74.
58. Zunino F, Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Des 1990; 5: 307-17.
59. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 1994; 91: 1781-5.
60. Capranico G, Kohn KW, Pommier Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res 1990; 18: 6611-9.
61. Chow KC, Ross WE. Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol Cell Biol 1987; 7: 3119-23.
62. Estey E, Adlakha RC, Hittelman WN, Zwelling LA. Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity. Biochemistry 1987; 26: 4338-44.
63. Markovits J, Pommier Y, Kerrigan D, Covey JM, Tilchen EJ, Kohn KW. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and LI210 leukemia cells. Cancer Res 1987; 47: 2050-5.
64. Ishida R, Miki T, Narita T, et al. Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 1991; 51: 4909-16.
65. Carl J. Drug-resistance patterns assessed from tumor marker analysis. J Natl Cancer Inst 1989; 81: 1631-9.
66. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl J Med 1987; 316: 1388-93.
67. Willingham MC, Richert ND, Cornwell MM, et al. Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells. J Histochem Cytochem 1987; 35: 1451-6.
68. Cornwell MM, Safa AR, Felsted RL, Gottesman MM, Pastan I. Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170-kDa protein detected by photoaffinity labeling. Proc Natl Acad Sci USA 1986; 83: 3847-50.
69. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
70. Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang JL, Fojo AT. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 1990; 265: 10073-80.
71. Nitiss J, Wang JC. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 1988; 85: 7501-5.
72. Gudkov AV, Zelnick CR, Kazarov AR, et al. Isolation of genetic suppressor elements, inducing resistance to topoisomerase H-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci USA 1993; 90: 3231-5.
73. Evans CD, Mirski SE, Danks MK, Cole SP. Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line. Cancer Chemother Pharmacol 1994; 34: 242-8.
74. Bugg BY, Danks MK, Beck WT, Suttle DP. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci USA 1991; 88: 7654-8.
75. Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 1989; 86: 9431-5.
76. Tan KB, Dorman TE, Falls KM, et al. Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res 1992; 52: 231-4.
77. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-99.
78. Yamazaki K, Isobe H, Hanada T, et al. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines. Cancer Chemother Pharmacol 1997; 39: 192-8.
79. Zaman GJ, Versantvoort CH, Smit JJ, et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 1993; 53: 1747-50.
80. Schuurhuis GJ, Broxterman HJ, Cervantes A, et al. Quantitative determination of factors contributing to doxorubicin resistance in multidnig-resistant cells. J Natl Cancer Inst 1989; 81: 1887-92.
81. Tanaka S, Aizawa K, Katayanagi N, Tanaka O. Flow cytometric analysis of early steps in development of adriamycin resistance in a human gastric cancer cell line. Jpn J Cancer Res 1994; 85: 86-92.
82. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, Norris MD. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 1994; 54: 5036-40.
83. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
84. DeVore RF, Corbett AH, Osheroff N. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinylamino)methane-sulfon-m-anisidide. Cancer Res 1992; 52: 2156-61.
85. Atassi G, Tassin JP. Drug interaction involving P-glycoprotein in relation to multidrug resistance. Int J Clin Pharmacol Ther Toxicol 1992; 30: 526-7.
86. Skovsgaard T. Circumvention of resistance to daunorubicin by N-acetyldaunorubicin in Ehrlich ascites tumor. Cancer Res 1980; 40: 1077-83.
87. Nutter LM, Cheng AL, Hung HL, Hsieh RK, Ngo EO, Liu TW. Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. Biochem Pharmacol 1991; 41: 1283-92.
88. Plowman J, Paull KD, Atassi G, et al. Preclinical antitumor activity of batracylin (NSC 320846). Invest New Drugs 1988; 6: 147-53.
89. Jasztold-Howorko R, Landras C, Pierre A, et al. Synthesis and evaluation of 9-hydroxy-5-methyl-(and 5,6-dimethyl)-6H-pyrido(4,3-b]carbazole-1-N[(dialkylamino)alkyl] carboxamides, a new promising series of antitumor olivacine derivatives. J Med Chem 1994; 37: 2445-52.
90. Atassi G, Pierre A, Guilbaud N, et al. A novel olivacine derivative, S16020-2 (NSC-659687): preclinical antitumor activity. In: Proc XVI Int Cancer Congr 1994; 16: abstr 314.
91. Guilbaud N, Kraus-Berthier L, Saint-Dizier D, et al. In vivo antitumor activity of S 16020-2, a new olivacine derivative. Cancer Chemother Pharmacol 1996; 38: 513-21.
92. Kraus-Berthier L, Guilbaud N, Leonce S, et al. Antitumor effect of S16020-2 against experimental lung carcinoma. Proc Am Ass Cancer Res 1995; 36: abstr 314.
93. Guilbaud N, Kraus-berthier L, Saint-Dizier D, et al. Antitumor activity of S 16020-2 in two orthotopic models of lung cancer. Anti-Cancer Drugs 1997; 8: 276-82.
94. Kraus-berthier L, Guilbaud N, Jan M, et al. Experimental antitumor activity of S16020-2 in a panel of human tumors. Eur J Cancer 1997; in press.
95. Koo HM, Monks A, Mikheev A, et al. Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res 1996; 56: 5211-6.
96. De Isabella P, Capranico G, Zunino F. The role of topoisomerase II in drug resistance. Life Sci 1991; 48: 2195-205.
97. Fry AM, Chresta CM, Davies SM, et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991; 51: 6592-5.
98. Mirski SE, Evans CD, Almquist KC, Slovak ML, Cole SP. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 1993; 53: 4866-73.
99. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-4.
100. Harker WG, Slade DL, Drake FH, Parr RL. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 1991; 30: 9953-61.
101. Hochhauser D, Harris AL. The role of topoisomerase II alpha and beta in drug resistance. Cancer Treat Rev 1993; 19: 181-94.
102. Woessner RD, Mattern MR, Mirabelli CK, et al. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Different 1991; 2: 209-14.
103. Negri C, Scovassi AI, Braghetti A, Guano F, Astaldi Ricotti GC DNA topoisomerase II beta: stability and distribution in different animal cells in comparison to DNA topoisomerase I and II alpha. Exp Cell Res 1993; 206: 128-33.
104. Sinha BK. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 1995; 49: 11-19.
105. Hecquet B. New molecules with potential antitumor effect. Bull Cancer (Paris) 1994; 81: 39S-46S.
106. Pommier Y, Kerrigan D, Hartman KD, Glazer RI. Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J Biol Chem 1990; 265: 9418-22.
107. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC, Kaufmann SH. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 1992; 52: 2268-78.
108. Orengo G, Noviello E, Cimoli G, et al. Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation. Jpn J Cancer Res 1992; 83: 1132-6.
109. Leonce S, Perez V, Anstet M, Pierre A, Atassi G. In vitro synergistic effect of tubulin interacting agents in combination with S16020-2, a new topoisomerase II inhibitor, Proc Am Ass Cancer Res 1997; 38: abstr 320.
110. Yalowich JC, Allan WP, Fields AP. Upregulation of DNA topoisomerase II phosphorylation: use of bryostatin 1/etoposide combination to circumvent drug resistance Proc Am Ass Cancer Res 1997; 38: abstr 21.